BusinessAccelerate Diagnostics Reports 191 Instruments Under Contract and 3x Revenue Growth for First Quarter 2017By Nasdaq OMXMay 3, 2017, 8:08 PM UTC
BusinessAccelerate Diagnostics Reports 191 Instruments Under Contract and 3x Revenue Growth for First Quarter 2017By Nasdaq OMXMay 3, 2017, 8:08 PM UTC
BusinessAccelerate Diagnostics Reports 191 Instruments Under Contract and 3x Revenue Growth for First Quarter 2017By Nasdaq OMXMay 3, 2017, 8:08 PM UTC
BusinessMelinta Therapeutics Updates Pyrrolocytosine and Enhanced Macrolide Programs at ECCMID Showcasing Company’s Structure-Based Drug DesignBy Nasdaq OMXApr 21, 2017, 1:56 PM UTC
BusinessMelinta Therapeutics Presentations at ECCMID Show Potential of Baxdela in Obese and other Challenging Patient TypesBy Nasdaq OMXApr 21, 2017, 1:37 PM UTC
BusinessMelinta Therapeutics Highlighting Activity of Baxdela as well as Progress on Macrolide and Pyrrolocytosine Candidates at ECCMID 2017By Nasdaq OMXApr 19, 2017, 6:43 PM UTC
BusinessAccelerate Diagnostics Schedules Call to Review First Quarter 2017 Results for May 3rdBy Nasdaq OMXApr 18, 2017, 9:53 PM UTC
BusinessAccelerate Diagnostics Names Tom Brown to Board of DirectorsBy Nasdaq OMXMar 15, 2017, 4:15 PM UTC
